To observe the effect of Ayurvedic medicine for the treatment of Osteoporosis in the Post Menopausal Women.

An exploratory study to assess the effect of Ayush Osto on the bone turnover markers among post-menopausal osteoporotic women. - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/07/090656

Enrollment

Registered

2025-07-10

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M00-M99- Diseases of the musculoskeletal system and connective tissue

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Women age less than 70 years with history of spontaneous amenorrhea for equal or more than 12 months. B M D T score at or below -2.5 measured by DXA Scan of Hip region proximal femur.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Change in Bone Formation [SerumProcollagen Type I N-terminal Propeptide, Alkaline phosphatase (Total and Bone specific), Osteocalcin] and Bone Resorption (Serum CTX) Markers level at the end of treatment i.e. on 180th day as compared to baseline.Timepoint: Change in Bone Formation [SerumProcollagen Type I N-terminal Propeptide, Alkaline phosphatase (Total and Bone specific), Osteocalcin] and Bone Resorption (Serum CTX) Markers level at the end of treatment i.e. on 180th day as compared to baseline.	—

Measure

Time frame

Change in Bone Formation [SerumProcollagen Type I N-terminal Propeptide, Alkaline phosphatase (Total and Bone specific), Osteocalcin] and Bone Resorption (Serum CTX) Markers level at the end of treatment i.e. on 180th day as compared to baseline.Timepoint: Change in Bone Formation [SerumProcollagen Type I N-terminal Propeptide, Alkaline phosphatase (Total and Bone specific), Osteocalcin] and Bone Resorption (Serum CTX) Markers level at the end of treatment i.e. on 180th day as compared to baseline.

—

Secondary

Measure	Time frame
Change in Quality of Life score by using Qualeffo-41 questionnaire at the end of treatment as compared to baseline. Incidence of fractures associated with the osteoporosis during the study. Change in hematological & biochemical parameters (Liver function test & Renal function tests) during (at 60th day) & end of the study period (at 180th day). Incidence of treatment emergent adverse events during study.Timepoint: Baseline & at end of the treatment i.e. on 180th day.	—

Measure

Time frame

Change in Quality of Life score by using Qualeffo-41 questionnaire at the end of treatment as compared to baseline. Incidence of fractures associated with the osteoporosis during the study. Change in hematological & biochemical parameters (Liver function test & Renal function tests) during (at 60th day) & end of the study period (at 180th day). Incidence of treatment emergent adverse events during study.Timepoint: Baseline & at end of the treatment i.e. on 180th day.

—

Countries

India

Contacts

Public ContactDr Rinku Tomar

Central Council for Research in Ayurvedic Sciences

drrinkutomer1977@gmail.com9888685874

Outcome results